论文部分内容阅读
目的探讨ER、PR在乳腺增生性疾病中的定量表达及其临床意义。方法通过免疫组化SP法和定量分析技术检测乳腺单纯性增生、非典型增生(轻度、中度、重度)及导管内癌各20例中ER、PR的表达情况,并用20例正常乳腺组织作对照。结果与正常乳腺组织、单纯性增生相比,非典型增生、导管内癌中ER、PR的表达量增加,有显著性差异(P<0.05);ER、PR在中度非典型增生的表达量>50%,与轻度非典型增生比较有显著差异,而与重度非典型增生、导管内癌比较差异无显著性。结论ER、PR的异常表达可能发生在乳腺癌发生过程中的早期,其定量表达可作为早期诊断癌前病变并估计预后的有效指标。
Objective To investigate the quantitative expression of ER and PR in breast hyperplasia and its clinical significance. Methods The expression of ER and PR in 20 cases of simple hyperplasia of mammary glands, atypical hyperplasia (mild, moderate and severe) and intraductal carcinomas was detected by immunohistochemical SP method and quantitative analysis technique. Twenty normal breast tissues As a control. Results Compared with normal breast tissue and simple hyperplasia, the expression of ER and PR in atypical hyperplasia and ductal carcinoma increased significantly (P <0.05). The expression of ER and PR in moderate atypical hyperplasia > 50%, with mild atypical hyperplasia were significantly different, but with severe atypical hyperplasia, intraductal carcinoma was no significant difference. Conclusion The abnormal expression of ER and PR may occur in the early stage of breast cancer. The quantitative expression of ER and PR can be used as an effective indicator for early diagnosis of precancerous lesions and prognosis.